Paul J Ross

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Masatoshi Kudo, Osamu Yokosuka, Gianluca Masi, 2017, The Lancet.